Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 8/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058855 | 0.88 | SLC6A2 (0.41) | OPRL1SLC6A2MAPT | |
| SCHEMBL3608555 | 0.85 | SLC6A2 (0.38) | OPRL1OPRM1KDM4ERECQLSLC6A2 | |
| SCHEMBL3603070 | 0.83 | SLC6A2 (0.40) | OPRL1OPRM1KDM4ERECQLHCRTR1 | |
| SCHEMBL3607587 | 0.81 | SLC6A2 (0.41) | OPRL1OPRM1KDM4ERECQLHCRTR1 | |
| SCHEMBL3603631 | 0.79 | SLC6A2 (0.41) | OPRL1SLC6A2MAPT | |
| SCHEMBL3598276 | 0.78 | SLC6A2 (0.41) | OPRL1SLC6A2 | |
| SCHEMBL3604966 | 0.78 | MEN1 (0.39) | OPRL1KDM4ERECQLSLC6A2MAPT | |
| SCHEMBL4059777 | 0.76 | HSP90AA1 (0.40) | OPRL1OPRM1KDM4ERECQLSLC6A2 | |
| SCHEMBL4063463 | 0.76 | SLC6A2 (0.39) | SLC6A2MAPT | |
| SCHEMBL3617303 | 0.76 | MEN1 (0.42) | OPRL1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | OPRL1 55/4885OPRM1 79/4885KDM4E 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.